NINDS Network for Excellence in Neuroscience: Clinical Research Site at UC Davis

NINDS神经科学卓越网络：加州大学戴维斯分校的临床研究网站(PI：克雷格·M·麦克唐纳，医学；这项提议通过更新位于加州萨克拉门托的加州大学戴维斯卫生系统的临床研究站点，为NINDS神经科学卓越网络(NeuroNEXT)做出贡献。加州大学戴维斯卫生系统是美国人口最多的州的首府，也是美国最多样化和一体化的城市之一。加州大学戴维斯分校NeuroNEXT临床研究站点将通过减轻神经系统疾病的负担，继续为NINDS的使命做出贡献，并贡献一个基础设施，扩展NINDS测试有希望的新疗法的能力，提高临床试验的效率，并在新的机会出现时迅速做出反应，以测试神经疾病患者的有希望的治疗方法。我们作为现有的NeuroNEXT网站的经验，加州大学戴维斯分校最全面的校园-加州大学系统中最全面的校园，强大的翻译研究基础设施位于全国公认的、经验丰富的和具有竞争力的更新的NIH CTSA(加州大学戴维斯分校CTSC)，神经科学研究优秀，来自加州大学加州大学辫子药物发现联盟的创新协作药物开发管道，该联盟是一个战略定位为促进社区拓展的全国远程医疗卓越中心，一个创新的信息学，如用于病例识别的系留元数据注册，以及访问在具有积极临床联系的高排名的区域医疗系统中管理的不同的神经疾病患者，所有这些都协同作用，使加州大学戴维斯分校继续成为NeuroNEXT网络的杰出临床研究网站。加州大学戴维斯分校NeuroNEXT的目标是：1)利用现有资源和专业知识作为NeuroNEXT中心，实施多中心神经科学临床试验，提高在加州大学戴维斯分校进行的试验的效率和质量；2)与加州大学戴维斯分校药物发现联盟合作，作为NeuroNEXT的核心资源，并作为整个翻译光谱创新治疗开发的催化剂；3)提供当地和地区社区外联，以改善患者招募和留住，并将社区合作伙伴充分纳入翻译研究企业；4)有效利用、多样化和利用临床试验的创新远程健康和信息资源；以及5)为不同的早期职业研究人员提供协作和创新的临床研究培训和支持性环境，以发展更多的研究技能，成为独立的临床研究人员。我们迄今取得的成就--地方、区域和国家--为未来的成功奠定了坚实的基础。

NINDS Network for Excellence in Neuroscience: Clinical Research Site at UC Davis (PI: Craig M. McDonald, MD; Sub‐PI: Michael Rogawski, MD, PhD) This proposal contributes to the NINDS Network for Excellence in Neuroscience (NeuroNEXT) by renewing a clinical research site at the University of California Davis Health System located in Sacramento, CA, the capital of the most populous state in the country and one of the most diverse and integrated cities in the U.S. The UC Davis NeuroNEXT clinical research site will continue to contribute to the mission of NINDS by reducing the burden of neurologic diseases, and contribute an infrastructure which expands the NINDS capability to test promising new therapies, increase the efficiency of clinical trials, and respond quickly as new opportunities arise to test promising treatments for people with neurological disorders. Our experience as an existing NeuroNEXT site, neuroscience research excellence at UC Davis ‐ the most comprehensive campus in the University of California system, a robust translational research infrastructure housed in a nationally recognized, experienced, and competitively renewed NIH CTSA (the UC Davis CTSC), neuroscience research excellence, an innovative collaborative drug development pipeline from the University of California UC BRAID Drug Discovery Consortium, a national center of excellence in telehealth strategically positioned to promote community outreach, an innovative informatics such as the Tethered Metadata Registry for case identification, and access to diverse patients with neurological disorders managed in a highly ranked regional health system with active clinical affiliations, all work synergistically to position UC Davis to continue to be an outstanding Clinical Research Site for the NeuroNEXT network. UC Davis NeuroNEXT aims to: 1) Leverage existing resources and expertise to serve as a NeuroNEXT hub for implementing multicenter neuroscience clinical trials, increasing the efficiency and quality of trials conducted at the UC Davis site; 2) Collaborate with the University of California UC BRAID Drug Discovery Consortium to serve as a core resource for NeuroNEXT and function as a catalyst for innovative therapeutic development across the translational spectrum; 3) Provide local and regional community outreach to improve patient recruitment and retention and fully integrate community partners into the translational research enterprise; 4) Efficiently utilize, diversify, and leverage innovative telehealth and informatics resources for clinical trials; and 5) Provide collaborative and innovative clinical research training and a supportive environment for diverse early‐career investigators to develop additional research skills and become independent clinical investigators. Our accomplishments to date – locally, regionally, and nationally – provide an outstanding foundation for future success.